None of these replace a prescription, and if youre managing a condition like type 2 diabetes or obesity, you need to see a healthcare provider before making major dietary changes
Can J Diabetes (2014) 38(5):36471.10.1016/j.jcjd.2014.05.001 67 KrasnerNMIdoYRudermanNBCacicedoJM
If your clothing may rub your incision, cover it with a small bandage
With the development of the first GIP/GLP-1 co-agonist, tirzepatide, there has been an exponential increase in the effectiveness of incretin-mimetic pharmacological therapy for weight control in obese patients with and without diabetes
Galindo is supported in part by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institute of Health (NIH) under award numbers P30DK111024, 1K23DK123384, 1R03DK138255, and 1U2CDK137135
Researchers running head-to-head incretin comparisons typically run Retatrutide alongside Tirzepatide (dual GIP/GLP-1) and Semaglutide (GLP-1 mono-agonist) to characterize the marginal contribution of glucagon-receptor activation